Neurocrine Biosciences (NASDAQ:NBIX) PT Raised to $169.00

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective boosted by equities researchers at Barclays from $150.00 to $169.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target would indicate a potential upside of 18.61% from the company’s previous close.

Several other research firms also recently commented on NBIX. The Goldman Sachs Group upped their target price on Neurocrine Biosciences from $134.00 to $153.00 and gave the company a “buy” rating in a research report on Thursday, January 25th. Mizuho raised their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, February 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, April 10th. StockNews.com raised Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 20th. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $145.83.

Neurocrine Biosciences Stock Down 0.4 %

NASDAQ NBIX traded down $0.55 during trading hours on Thursday, hitting $142.48. The company’s stock had a trading volume of 404,614 shares, compared to its average volume of 850,797. Neurocrine Biosciences has a twelve month low of $89.04 and a twelve month high of $148.37. The firm has a market capitalization of $14.18 billion, a P/E ratio of 58.94 and a beta of 0.28. The stock has a fifty day moving average of $137.11 and a 200 day moving average of $128.51.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. The business had revenue of $515.20 million for the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. Neurocrine Biosciences’s revenue for the quarter was up 25.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.88 EPS. On average, analysts predict that Neurocrine Biosciences will post 4.8 earnings per share for the current year.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Richard F. Pops sold 15,000 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the completion of the sale, the director now directly owns 29,512 shares in the company, valued at $3,909,454.64. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, Director Richard F. Pops sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total value of $1,987,050.00. Following the sale, the director now owns 29,512 shares in the company, valued at $3,909,454.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David W. Boyer sold 456 shares of Neurocrine Biosciences stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $141.96, for a total transaction of $64,733.76. Following the transaction, the insider now owns 4,894 shares in the company, valued at approximately $694,752.24. The disclosure for this sale can be found here. Insiders sold a total of 181,547 shares of company stock worth $25,039,887 over the last three months. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Neurocrine Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. boosted its position in Neurocrine Biosciences by 10.5% during the fourth quarter. First Horizon Advisors Inc. now owns 782 shares of the company’s stock worth $103,000 after acquiring an additional 74 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Neurocrine Biosciences by 3.2% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,530 shares of the company’s stock worth $333,000 after acquiring an additional 78 shares during the last quarter. Quadrant Capital Group LLC boosted its position in Neurocrine Biosciences by 3.9% during the fourth quarter. Quadrant Capital Group LLC now owns 2,075 shares of the company’s stock worth $273,000 after acquiring an additional 78 shares during the last quarter. Sunbelt Securities Inc. boosted its position in Neurocrine Biosciences by 34.3% during the third quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock worth $37,000 after acquiring an additional 83 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its position in Neurocrine Biosciences by 0.6% during the first quarter. Commonwealth Equity Services LLC now owns 13,941 shares of the company’s stock worth $1,923,000 after acquiring an additional 84 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.